Role Overview
The Clinical Imaging Scientific Director for Oncology will own the strategy and execution of sophisticated early and late phase oncology imaging in clinical trials where imaging plays a key role. Imaging includes all modalities with a special focus on PET and CT. The successful candidate will develop imaging endpoints and biomarkers, drive the scientific imaging aspects, and oversee tumor response assessment of oncology clinical studies.
Location
Tarrytown, NY
Responsibilities
- Create fit‑for‑purpose imaging biomarker strategies and collaborate with research, clinical imaging, and oncology therapeutic areas to develop imaging endpoints that inform and advance the Regeneron clinical pipeline.
- Prepare and present clinical imaging strategies to senior management.
- Manage a complex network of stakeholders across Regeneron.
- Lead the design and implementation of multi‑modality imaging measures as endpoints for oncology therapeutic clinical studies.
- Collaborate closely with Regeneron clinical teams as imaging subject matter experts to ensure optimal design and execution of imaging strategy, including development of protocols, imaging endpoints, imaging manuals, imaging charters, statistical analysis plans, and clinical study reports.
- Work with Clinical Imaging Operations and imaging contract research organizations to ensure flawless conduct and data integrity of studies’ imaging components and endpoints.
- Serve as Study Scientific Director for clinical trials focused on qualification and utilization of novel imaging biomarkers.
- Lead interactions with regulatory agencies for communications regarding imaging endpoints and procedures, and with site ethics committees for approval of clinical imaging biomarker development studies.
Qualifications
- PhD program with a minimum of 10+ years of clinical imaging experience, including at least 7 years within oncology drug development.
- Superior written and verbal communication and organizational skills.
- Experience implementing central efficacy assessments using tumor response criteria such as RECIST 1.1, iRECIST, PCWG3, Lugano, and IMWG in oncology clinical trials.
- Successful engagement experience with regulatory agencies and the ability to champion imaging innovations and lead projects effectively.
- Experience as study scientific director of PET imaging biomarker clinical trials in oncology.
- Experience applying PET imaging as a quantitative endpoint in clinical and preclinical studies in oncology.
Benefits
Regeneron offers a competitive total rewards package that may include:
- Annual bonuses or other incentive plans
- Equity awards
- Pension or retirement benefits (401(k) with company match)
- Health, dental, vision, life, and disability insurance
- Paid time off and family support benefits
- Additional wellness programs and fitness center access
The final offer will be determined within the relevant salary range of \$205,000.00 – \$341,600.00 based on country of employment, role level, and skills and experience.Equal Employment Opportunity Statement
Regeneron is an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion or belief (or lack thereof), sex, sexual orientation, gender identity or expression, gender reassignment, marital or civil partnership status, civil status, pregnancy or parental status, age, disability, nationality, citizenship status, ethnic or national origin, membership of the Traveler community, familial status, genetic information, military or veteran status, or any other characteristic protected under applicable law. Where required, Regeneron will provide reasonable accommodation to applicants with known disabilities or chronic illnesses during the recruitment process, unless such accommodation would impose undue hardship.
#J-18808-Ljbffr